Oruka Therapeutics Statistics
Total Valuation
ORKA has a market cap or net worth of $410.35 million. The enterprise value is $38.25 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ORKA has 37.44 million shares outstanding.
Current Share Class | 37.44M |
Shares Outstanding | 37.44M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | -4.97% |
Owned by Insiders (%) | 2.52% |
Owned by Institutions (%) | 59.75% |
Float | 22.63M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.13 |
P/TBV Ratio | 1.13 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.03, with a Debt / Equity ratio of 0.00.
Current Ratio | 30.03 |
Quick Ratio | 29.78 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -81.79 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -31.06% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.87M |
Employee Count | 28 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.40% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -73.40% |
50-Day Moving Average | 10.01 |
200-Day Moving Average | 18.93 |
Relative Strength Index (RSI) | 55.45 |
Average Volume (20 Days) | 142,994 |
Short Selling Information
The latest short interest is 2.72 million, so 7.26% of the outstanding shares have been sold short.
Short Interest | 2.72M |
Short Previous Month | 2.66M |
Short % of Shares Out | 7.26% |
Short % of Float | 12.02% |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -113.48M |
Pretax Income | n/a |
Net Income | -80.35M |
EBITDA | n/a |
EBIT | -113.48M |
Earnings Per Share (EPS) | -$3.04 |
Full Income Statement Balance Sheet
The company has $349.09 million in cash and $947,000 in debt, giving a net cash position of $372.10 million or $9.94 per share.
Cash & Cash Equivalents | 349.09M |
Total Debt | 947,000 |
Net Cash | 372.10M |
Net Cash Per Share | $9.94 |
Equity (Book Value) | 364.73M |
Book Value Per Share | 9.66 |
Working Capital | 340.36M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$83.80 million and capital expenditures -$219,182, giving a free cash flow of -$84.02 million.
Operating Cash Flow | -83.80M |
Capital Expenditures | -219,182 |
Free Cash Flow | -84.02M |
FCF Per Share | -$2.24 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ORKA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -19.58% |
FCF Yield | -20.47% |
Dividend Details Analyst Forecast
The average price target for ORKA is $39.71, which is 262.65% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $39.71 |
Price Target Difference | 262.65% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on September 3, 2024. It was a reverse split with a ratio of 0.083333333:1.
Last Split Date | Sep 3, 2024 |
Split Type | Reverse |
Split Ratio | 0.083333333:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |